XML 38 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2017
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

 

    As of March 31, 2017     Fair Value Measurements  
    Carrying     Fair     As of March 31, 2017  
    Amount     Value     Level 1     Level 2     Level 3  
Assets:                              
Cash and cash equivalents:                                        
Cash   $ 7,126     $ 7,126     $ 7,126     $ - #   $ -  
    $ 7,126     $ 7,126     $ 7,126     $ -     $ -  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 1,561     $ 1,561     $ -     $ -     $ 1,561  
Derivative liability:                                        
Embedded conversion derivative   $ 51     $ 51     $ -     $ -     $ 51  
    $ 1,612     $ 1,612     $ -     $ -     $ 1,612  

 

As of December 31, 2016     Fair Value Measurements    
    Carrying     Fair     As of December 31, 2016  
    Amount     Value     Level 1     Level 2     Level 3  
Assets:                              
Cash and cash equivalents:                                        
Cash   $ 602     $ 602     $ 602     $ -     $ -  
    $ 602     $ 602     $ 602     $ -     $ -  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 1,545     $ 1,545     $ -     $ -     $ 1,545  
RedPath     5,969       5,969       -       -       5,969  
    $ 7,514     $ 7,514     $ -     $ -     $ 7,514

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the contingent consideration and also the embedded conversion option from continuing operations from January 1, 2017 to March 31, 2017 is as follows:

 

    2017  
                            Cancellation              
          Initial                 of Obligation/     Mark to        
    January 1,     Liability     Payments     Accretion     Conversions     Market     March 31,  
Asuragen   $ 1,545             $ (25 )   $ 41     $ -     $ -     $ 1,561  
Redpath     5,969               -       -       (5,969 )     -       -  
Embedded conversion option     -       208       -               (199 )     42       51  
    $ 7,514     $ 208     $ (25 )   $ 41     $ (6,168 )   $ 42     $ 1,612  

Schedule of Assumptions Used in Black-Scholes Option Pricing Model

The following table sets forth the assumptions used in the Black-Scholes Option Pricing Model to estimate the fair value of the embedded conversion option derivative liability as of March 31, 2017:

 

    March 31, 2017  
       
Market Price   $ 2.63  
Exercise Price   $ 2.44  
Risk-free interest rate     0.99 %
Expected volatility     234.05 %
Expected life in years     1.25  
Expected dividend yield     0.00